Spero TherapeuticsSPRO.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Spero Therapeutics (SPRO.O) trades at a P/E of 8.67x, P/B of 1.45x, P/S of 1.36x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 45th percentile over the trailing 10Y window (vs. 45th percentile over 3Y); P/B sits at the 32nd percentile over the trailing 10Y window (vs. 52nd percentile over 3Y); P/S sits at the 21st percentile over the trailing 10Y window (vs. 54th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 10th percentile within its industry and the 14th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Cross-checking P/E against P/B, the two percentiles sit within 13.1 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Spero Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: SPRO · SPRO
Want the full picture on whether Spero Therapeutics (SPRO.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 8.67 | ||||||
| P/B (MRQ) | 1.45 | ||||||
| P/S (TTM) | 1.36 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |